Big Pharma

Big Pharma Undercuts California Generic Insulin Plan

Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin scheme.

Eli Lilly to Buy Loxo for $8 Billion

Innovative Companies Have to Deal with Risks

Bridging the Innovation Gap

The Art of the Alliance

After Pharma’s Patent Cliff

Chances and Hurdles for Biosimilars

Discovering the Future of Pharma

Giving Pharma a Boost

Opportunities Through Biotechnology

Evolution of a Dynamic Healthcare Market

Essential Ingredients

ICIG is Looking to Expand its Two Major Platforms

Standing Out in Global Pharmaceutical Contract Manufacturing Market

Outsourcing Biopharmaceutical Manufacturing

A Shaky Platform?

Drug Industry CEOs Plotting More Carve-outs

Drugmakers Eye Africa's Middle Classes as Next Growth Market

Pharma vs. the World

India Revokes Roche Patent in New Blow for Big Pharma

The European Pharmaceuticals Economy at Halftime 2012

Venture Firms See Signs of Rebirth in Life Sciences

Showdown for Big Pharma in India's Highest Court

Small Generic Drug Firms Need Niches to Survive Looming Price War

The Pharmaceutical Supply Chain

India to Give Free Generic Drugs to Hundreds of Millions

Pharma Asks The Money Question Earlier For New Drugs

Big Pharma Stocks Could Rally in the Next Year